Last reviewed · How we verify
Influenza vaccine GSK2186877A
Influenza vaccine GSK2186877A is a Influenza vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Influenza prevention.
GSK2186877A is an investigational influenza vaccine designed to stimulate immune responses against influenza virus through antigen presentation and adaptive immunity.
GSK2186877A is an investigational influenza vaccine designed to stimulate immune responses against influenza virus through antigen presentation and adaptive immunity. Used for Influenza prevention.
At a glance
| Generic name | Influenza vaccine GSK2186877A |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
As an influenza vaccine candidate, GSK2186877A likely works by presenting influenza antigens to the immune system to generate both humoral (antibody) and cellular (T-cell) immune responses. This primes the body to recognize and rapidly respond to natural influenza infection, reducing disease severity and transmission. The specific formulation or adjuvant strategy employed by GSK distinguishes this candidate from existing seasonal influenza vaccines.
Approved indications
- Influenza prevention
Common side effects
- Injection site reactions (pain, erythema, swelling)
- Myalgia
- Headache
- Fatigue
Key clinical trials
- Trial to Evaluate the Safety and the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Healthy Children (PHASE1)
- Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine in Elderly People (PHASE3)
- Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine for the Elderly (PHASE3)
- Evaluation of Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Years and Older (PHASE3)
- Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly (PHASE3)
- Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older (PHASE3)
- Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Influenza vaccine GSK2186877A CI brief — competitive landscape report
- Influenza vaccine GSK2186877A updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Influenza vaccine GSK2186877A
What is Influenza vaccine GSK2186877A?
How does Influenza vaccine GSK2186877A work?
What is Influenza vaccine GSK2186877A used for?
Who makes Influenza vaccine GSK2186877A?
What drug class is Influenza vaccine GSK2186877A in?
What development phase is Influenza vaccine GSK2186877A in?
What are the side effects of Influenza vaccine GSK2186877A?
Related
- Drug class: All Influenza vaccine drugs
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Influenza prevention
- Compare: Influenza vaccine GSK2186877A vs similar drugs
- Pricing: Influenza vaccine GSK2186877A cost, discount & access